Turning Back the Clock
2026 marks a landmark year for geroscience as cellular reprogramming therapies move into human clinical trials for vision restoration.
Yamanaka Factors in Action
The use of specific transcription factors to 'reset' the epigenetic age of retinal ganglion cells is offering hope for treating conditions like glaucoma.
Official Insight
Reports from Prof. Richard Barker highlight the 2026 FDA approval of Life Biosciences trials for cellular reset.
Strategic Data Expansion 2026.4
This approach does not change the DNA sequence but restores the 'software' of the cell to a more youthful state.
[Illustration of a cell undergoing epigenetic reprogramming back to a youthful state]
By late 2026, researchers are investigating if this same technology can be applied to other tissues, such as the heart and kidney, to reverse organ-specific aging.